How high doses of intravenous IgG (IVIG) suppress autoimmune diseases remains unresolved. We have recently shown that the antiinfl ammatory activity of IVIG can be attributed to a minor species of IgGs that is modifi ed with terminal sialic acids on their Fc-linked glycans. Here we propose that these Fc-sialylated IgGs engage a unique receptor on macrophages that, in turn, leads to the upregulation of an inhibitory Fcγ receptor (FcγR), thereby protecting against autoantibody-mediated pathology.
IgG antibodies are the primary mediators of protective humoral immunity against pathogens, but they can also be pathogenic. Acting as cytotoxic molecules or as immune complexes, IgG autoantibodies are the principal mediators of autoimmune diseases such as immune thrombocytopenia (ITP), autoimmune hemolytic anemia (AHA), and systemic lupus erythematosus (SLE), and may contribute to other autoimmune diseases, such as rheumatoid arthritis (RA), type I diabetes, and multiple sclerosis (1) . IgG antibodies have been used therapeutically for over a century. They were fi rst used as antitoxins for the treatment of infectious diseases in the preantibiotic era (1, 2) . Today, hyperimmune sera from human donors recovering from infection with specifi c viruses, such as hepatitis B, cytomegalovirus, and varicella zoster, are used to provide protective immunity to susceptible populations. In addition, pooled polyclonal IgG from the serum of thousands of donors is currently used to provide replacement IVIG therapy for patients lacking immunoglobulins (3) . At high doses (1 g/kg), IVIG is also widely used as an antiinfl ammatory agent for the treatment of autoimmune diseases. This approach is based on an observation made in 1981 that administration of IVIG attenuated platelet clearance in a child with ITP (4). Since then, high dose IVIG has been widely used to treat patients with immune system disorders and is FDA approved for the treatment of ITP and Kawasaki's Disease, an acute vasculitic syndrome, in addition to humoral immunodefi ciency and bone marrow transplantation. Off label uses include the treatment of RA, SLE, multiple sclerosis, and scleroderma. Demand for IVIG has been increasing in recent years, resulting in shortages and restrictions in its use. In the United States, over 4 million grams of IVIG was used in 2004 at a cost of $500 million, more than half of which was off label use.
The mechanisms by which high doses of pooled, monomeric IgG provide antiinfl ammatory activity have been the subject of much speculation, stemming from the fact that IgGs can form many diff erent binding interactions through both their antigen binding and Fc domains. In this commentary, we will address the current models of IVIG antiinfl ammatory activity and review recent results that argue against these models and support an alternative, novel mechanism of action. This new model accounts for the high dose requirement for IVIG in infl ammatory diseases and for the dominant role of the Fc portion of the molecule, and suggests ways to improve therapeutics for autoimmune diseases.
Fc is key
In some cases, antigen binding alone might be suffi cient to mediate the antiinfl ammatory eff ects attributed to IVIG, for example, by blocking interactions between a proinfl ammatory ligand and its receptor or by neutralizing its ability to elicit an infl ammatory response. This Fab-mediated mechanism appears to underlie the therapeutic activity of IVIG in the treatment of toxic epidermal necrolysis, which has been attributed to inhibition of Fas-mediated epidermal cell death by antagonistic anti-Fas antibodies in the IVIG preparation (5). However, a generalized role for the antigen binding domain in the antiinfl ammatory activity of IgG is unlikely given that intact IVIG and its Fc fragments have equivalent antiinfl ammatory activity both in the clinical treatment of ITP (6) and in many animal models (7) (8) (9) . We will therefore focus on the mechanisms by which the Fc region of IgG may function as an antiinfl ammatory molecule.
How IgG autoantibodies infl ame: activating Fc Rs, neonatal Fc receptor, and complement
To understand how IVIG reverses infl ammation in autoimmune disease, it is helpful to consider how IgG autoantibodies cause infl ammation. The IgG Fc region couples antigen recognition to several eff ector pathways, most notably the system of activating and inhibitory FcγRs, the complement family of molecules and their receptors, and the neonatal Fc receptor (FcRn) pathway, which is required for the extended in vivo half-life of IgG antibodies (10) (11) (12) (13) . Studies in animal systems and correlative studies in human populations show that the proinfl ammatory activities of IgG require the interaction of the Fc fragment of the antibodies with their cognate cellular FcγRs (1). Most hematopoietic cells express both activating and inhibitory FcγRs. The in vivo activity of an IgG antibody thus results from the net eff ect of engaging both classes of receptors, which, in turn, is governed by the respective affi nity constants of individual IgG subclasses for specifi c FcγRs (14) .
FcγRs for IgG are the primary mediators of the proinfl ammatory activity of IgG in the immunopathology of autoimmune diseases and are required for the protective action of IgG therapeutics, such as the anti-CD20 monoclonal antibody (mAb) used to treat lymphoma. Thus, mice rendered genetically defi cient in the activating FcγRs are protected from the pathogenic consequences of autoantibodies in many disease models, including SLE, RA, ITP, AHA, and Goodpasture's Disease (10) . And tumor-specifi c mAbs (IgG), designed to clear tumors, also fail to protect these mice (15) . Studies in humans have similarly shown that the clinical response to antitumor antibodies depends on activating FcγR genes. Indeed, patients with FcγR alleles that confer higher binding activity to the therapeutic IgG have improved clinical outcomes (16) (17) (18) . FcγR alleles that confer hyperresponsiveness to IgG immune complexes are also associated with autoimmune disease susceptibility in defi ned populations (1) .
In contrast to FcγRs, animal studies have generally failed to demonstrate a substantial contribution of the classical pathway of complement activation in models of IgG-mediated infl ammation. Mice defi cient in the C3 component of complement, for example, are not protected from IgG-mediated cytotoxicity for complement-fi xing antibodies in models of red cell, platelet, or B cell clearance (19) . In several models of immune complex-mediated infl ammation, C3 has been shown to be dispensable as well (20) . In some models of IgGmediated infl ammation C5a receptor (C5aR)-defi cient mice are protected (21, 22) . In those cases where C5aR defi ciency leads to protection, the proposed mechanism is not through classical or alternative complement pathway activation of C5a, but rather through a direct activation of C5a by FcγR crosslinking on eff ector cells, which in turn results in C5aR-triggered up-regulation of FcγR expression on these eff ector cells (21, 23) .
Similar to mice lacking the activating FcγRs, mice defi cient in FcRn are protected from pathogenic autoantibodies. The long serum half-life of IgG results from its interaction with FcRn, a major histocompatibility complex class I homologue that associates with β2-microglobulin and is expressed on endothelial cells. FcRn remains bound to internalized IgG at the acidic pH of the lysosomal vesicle, preventing its intracellular degradation and allowing it to be recycled to the extracellular milieu (12, 13, 24) . Disruption of the FcRn pathway in mice results in the rapid clearance of all IgG antibodies, including pathogenic autoantibodies, which protect these mice from autoantibodydriven infl ammation (25) (26) (27) .
The antiinfl ammatory activity of IVIG
Three possible modes of action have been proposed to account for the antiinfl ammatory activity of the Fc fragments of IVIG. These models take into account the mechanisms by which autoantibodies trigger infl ammation and the high doses of IVIG that are required for protection (Fig. 1) .
Since the in vivo data on the pathogenicity of IgG autoantibodies and immune complexes do not generally support a role for the components of the complement cascade in autoantibody-driven infl ammation, we will not consider that pathway in the mechanisms of IVIG. (28) . Although this model recognizes the primary role of FcγRs in the pathogenesis of autoimmune-mediated infl ammation, it fails to take into account the low affi nity of these receptors. IgGs interact with activating FcγRs (FcγRIII and IV) with affi nity constants in the range of 10 −6 to 10 −7 . This ensures that these receptors are activated by IgG immune complexes, which can form high avidity interactions, and not by monomeric,
In fact, at high doses of IgG, the resulting saturation of FcRn increases IgG catabolism, thus restoring the circulating concentration of IgG to a relatively narrow range. The fact that mAbs that block activating FcγRs mimic the antiinfl ammatory activity of IVIG simply refl ects the fact that pathogenic immune complexes trigger infl ammation through these activation receptors; it does not indicate that IVIG and anti-FcγRs mAbs have a common mechanism of action (9, 28) . Indeed, as will be described below, the antiinfl ammatory activity of IgGs in IVIG preparations increases as their affi nity for activating FcγRs decreases.
Model 2: high dose IgG saturation of
FcRn. An alternative scenario to model 1 is that saturation of FcRn by high levels of exogenous IgG leads to the catabolism of pathogenic autoantibodies. It is diffi cult to evaluate this theory experimentally, however, as removing or blocking FcRn in mice results in a rapid clearance of exogenous autoantibodies and drastically reduced serum IgG levels (27) . Investigations of the eff ect of IVIG in FcRn-defi cient mice have relied either on repeated infusion of IVIG, a situation that does not accurately model the use of IVIG, or evaluation of the purported protective eff ect of IVIG at time points far beyond the peak of the disease. For example, a common animal model used to evaluate IVIG action is platelet depletion in mice mediated by an antiplatelet antibody. In this model, platelet consumption reaches a nadir 4 hours after introduction of the cytotoxic antibody; IVIG prevents platelet depletion through this time point. In FcRn-defi cient mice, however, IVIGinduced protection against platelet depletion is not observed until 48-72 h after infusion of the cytotoxic antibody (25, 29) . In another model, human polyclonal antibodies found in human bullous diseases (bullous pemphigoid, pemphigus foliaceus, and pemphigus vulgaris) were passively transferred to neonatal mice to induce disease. IVIG protected wild-type mice but did not protect neonatal FcRn-defi cient mice. Little is known about the mechanisms by which these human antibodies trigger disease in this model or about the expression of FcγRs or FcRn in neonatal mice, making it diffi cult to draw any general conclusions about the mechanism of IVIG protection (26) .
Ruling out a role for FcRn saturation in the antiinfl ammatory activity of IVIG would require an IVIG preparation that binds FcRn and has a normal serum half-life but has no antiinfl ammatory activity. There are several experimental systems that fulfi ll these requirements. Deglycosylation of the conserved, Asn297 N-linked glycan on IgG or its Fc fragment with PNGase, for example, yields an IVIG preparation that retains FcRn binding and normal serum half-life but lacks its antiinfl ammatory activity (30, 31) . Desialylation of the terminal sialic acid residues on the Asn297-linked glycan of IVIG has the same eff ect (31) . Thus, if saturation of FcRn by high dose IVIG is involved in its antiinfl ammatory mechanism of action, these glycan-modifi ed preparations of IVIG should not have lost activity. Conversely, enriching IVIG for sialylated Fc glycoforms enhances its antiinfl ammatory activity, thus reducing the dose of IVIG required for protection without aff ecting the half-life of either the IVIG antibodies (31) or the pathogenic mouse serum antibodies (unpublished data). Again, this provides evidence against a role for FcRn in the antiinfl ammatory activity of IVIG. inhibitory receptors (by glycosylation modifi cations, for example) or modulating the absolute cell surface levels of these receptors will change the IgG concentration required to trigger cellular activation. In models of ITP, AHA, RA, and nephrotoxic nephritis, the ability of IVIG to protect mice from pathogenic IgG antibody-driven responses depends on FcγRIIB (7-9, 25, 31, 32) . The only other mouse strain in which IgG-mediated infl ammation occurs but IVIG protection is lost is the op/op mouse, in which loss of the hematopoietic growth factor colony-stimulating factor (CSF)-1 results in a depletion of CSF-1-dependent macrophage populations (7) . IVIG administration to normal mice, but not op/op mice, increases the surface expression of FcγRIIB on a population of CSF-1-independent, "eff ector" macrophages in the spleen (Fig. 2) . These results imply that two different macrophage subsets are involved in the mechanism of IVIG actiona subset that is dependent on CSF-1 (and thus absent in op/op mice) that may act as a "regulator" of IVIG, and a CSF-1-independent, eff ector subset, which mediates the infl ammatory responses to IgG-FcγR cross-linking. By engaging the regulatory macrophage, IVIG triggers a suppressive pathway that attenuates the ability of the eff ector macrophages to respond to cytotoxic or immune-complexed IgG that cross-link activating FcγRs. This inhibition involves increasing the surface expression of the inhibitory FcγRs, thereby raising the threshold required for triggering activating FcγRs. The mechanism by which IVIG engaged regulatory macrophages, which then triggered the up-regulation of inhibitory FcγRs expression on the eff ector population, remained unknown. In other words, we did not yet know what was distinctive about the IgG in IVIG that promoted this antiinfl ammatory activity.
Why are high doses of IVIG results required?
If IVIG does not work by blocking FcγRs or FcRn, why are such high doses required? Recently, we explored the hypothesis that the antiinfl ammatory activity of IVIG depends on a specialized subset of IgG that is present at limiting concentrations in the IVIG preparation. The glycosylation requirement for IVIG activity suggested that a specifi c glycoform of the Asn297-linked glycan may be involved in the antiinfl ammatory activity. Because over 30 glycoforms are found at this position in human serum, the pooled serum used to prepare IVIG may contain limiting amounts of the antiinfl ammatory IgG glycoform. We tested this hypothesis by fractionating IVIG and its Fc fragments by sialic acid-specifi c lectin (SNA) affi nity chromatography and found that 1-2% of unfractionated IVIG has sialic acid at the Asn297-linked glycan. Enrichment by SNA binding increased the sialic acid content to 20% with a concomitant 10-fold increase in its antiinfl ammatory activity. In a mouse model of RA, 100 mg/kg of sialic acid-enriched IVIG protected as well as 1 g/kg of unfractionated IVIG. Further enrichment for the active glycoform of IgG should reduce this concentration requirement to 20 mg/kg or below. No diff erence was observed in the serum half-life of the SNA-enriched IVIG compared with total IVIG, or in its requirement for FcγRIIB expression (31) . These results are consistent with the model proposed in Fig. 2 , in which the sialylated IgG in normal serum engages a regulatory macrophage receptor with specifi city for the sialylated form of IgG, triggering an inhibitory pathway that ultimately results in the up-regulation of inhibitory FcγR expression on eff ector macrophages. One candidate for the regulatory macrophage receptors are the siglec family of receptors (33) , which bind sialic acid and have been suggested to mediate inhibitory signals via ITIM sequences found in their cytoplasmic domains.
Others have proposed that IVIG cross-linking of activating FcγRs on dendritic cells may contribute to the antiinfl ammatory eff ects of IVIG in a model of ITP (24) . These fi ndings suggest that under some experimental conditions, ex vivo stimulation of dendritic cell populations through activating FcγRs may trigger antiinfl ammatory responses, perhaps by promoting the diff erentiation or survival of regulatory T cells. It is unlikely, however, that this mechanism is relevant to IVIG activity, as antibodies enriched in sialic acid show reduced binding to activating FcγRs yet display enhanced antiinfl ammatory activity (27) . The reduced binding of the active glycoforms of IgG in IVIG to activating FcγRs bolsters the argument against the simple competition mechanism of IVIG action proposed in model 1.
Concluding remarks
The observation that IVIG activity is caused by a limiting concentration of a sialic acid-bearing IgG glycoform provides the rationale for the preparation of a sialic acid-enriched IVIG product that would confer greater antiinfl ammatory activity at doses 1/10 to 1/100 currently required. It also suggests that a fully recombinant IVIG composed of hypersialylated IgG would be a potent antiinfl ammatory agent for use in autoimmune diseases. The identity of the macrophage receptor involved in the binding of sialylated IgG and the characterization of the inhibitory pathways induced by sialylated IgG will provide insights into the normal biological functions of sialylated IgG in vivo and the homeostatic pathways that regulate IgG eff ector activity.
